瑞思迈 RMD 深 沪
等待开盘 10-13 09:30:00 美东时间
234.60
+4.550
+1.98%
华盛通- 最 高235.98
- 今 开231.74
- 成交量 105.12万股
- 最 低 230.08
- 昨 收 230.05
- 总市值 329.94亿
- 52周最高 275.81
- 市盈率 静 22.49
- 换手率 0.75%
- 52周最低 179.605
- 委 比 -80.33%
- 总股本 1.41亿
- 历史最高 291.35
- 量 比 1.11
- 振 幅 2.56%
- 历史最低 3.47
- 每 手 1
- 风险率 22.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:R...
10-09 10:22
ResMed Awards Performance-Based Stock Units to Chief Product Officer
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ...
10-02 07:07
ResMed CEO Farrell Earns Performance-Based Stock Grant
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:R...
10-02 07:07
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
加拿大皇家银行资本市场上调医疗设备与数字健康企业ResMed评级
医疗设备与数字健康企业ResMed（RMD）周二股价上涨近 5%，此前加拿大皇家银行资本市场将该股评级由 “行业表现” 上调至 “跑赢大盘”。 该机构同时...
09-16 00:12
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
09-15 22:16
ResMed upgraded at RBC Capital Markets on Q4 positives
RBC Capital Markets on Tuesday upgraded ResMed (RMD) to Outperform from Sector Perform and raised its price target to $262 from $244, citing positives in the respiratory device maker’s Q4 results for ...
09-15 22:00
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.
08-31 20:24
